Combination Therapy with Finerenone and Sodium-Glucose Cotransporter Inhibitors
- 5 March 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 661-663
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and AlbuminuriaJAMA, 2026
- Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or BothJournal of the American Society of Nephrology, 2025
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 DiabetesNew England Journal of Medicine, 2025
- Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic DiseasesKidney360, 2023
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 DiabetesNew England Journal of Medicine, 2021
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysisEuropean Heart Journal, 2021
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trialsThe Lancet Diabetes & Endocrinology, 2019